Home Healthcare Pharmaceuticals Targeted Protein Degradation Market

Targeted Protein Degradation Market Size, Share & Trends Analysis Report By Type (PROTAC, Molecular Glues, LYTACs, Others), By Application (Drug Discovery, Therapy Development, Cancer, Neurology, Infectious Diseases, Cardiovascular Diseases, Others), By End Use (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals & Clinical Laboratories, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Dhanashri B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Targeted Protein Degradation Market, By Type 2022-2034 (USD MILLION/ Units)
    1. PROTAC
    2. Molecular Glues
    3. LYTACs
    4. Others
  2. Targeted Protein Degradation Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Drug Discovery
    2. Therapy Development
    3. Cancer
    4. Neurology
    5. Infectious Diseases
    6. Cardiovascular Diseases
    7. Others
  3. Targeted Protein Degradation Market, By End Use 2022-2034 (USD MILLION/ Units)
    1. Pharmaceutical & Biotechnology Companies
    2. Academic & Research Institutes
    3. Hospitals & Clinical Laboratories
    4. Others
  4. Regional Targeted Protein Degradation Market
    1. North America
      1. North America Targeted Protein Degradation Market By Type 2022-2034 (USD MILLION/ Units)
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
      2. North America Targeted Protein Degradation Market By Application 2022-2034 (USD MILLION/ Units)
        1. Drug Discovery
        2. Therapy Development
        3. Cancer
        4. Neurology
        5. Infectious Diseases
        6. Cardiovascular Diseases
        7. Others
      3. North America Targeted Protein Degradation Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical & Biotechnology Companies
        2. Academic & Research Institutes
        3. Hospitals & Clinical Laboratories
        4. Others
      4. U.S.
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      5. Canada
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
    2. Europe
      1. Europe Targeted Protein Degradation Market By Type 2022-2034 (USD MILLION/ Units)
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
      2. Europe Targeted Protein Degradation Market By Application 2022-2034 (USD MILLION/ Units)
        1. Drug Discovery
        2. Therapy Development
        3. Cancer
        4. Neurology
        5. Infectious Diseases
        6. Cardiovascular Diseases
        7. Others
      3. Europe Targeted Protein Degradation Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical & Biotechnology Companies
        2. Academic & Research Institutes
        3. Hospitals & Clinical Laboratories
        4. Others
      4. U.K.
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      5. Germany
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      6. France
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      7. Spain
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      8. Italy
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      9. Russia
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      10. Nordic
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      11. Benelux
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      12. Rest of Europe
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
    3. APAC
      1. APAC Targeted Protein Degradation Market By Type 2022-2034 (USD MILLION/ Units)
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
      2. APAC Targeted Protein Degradation Market By Application 2022-2034 (USD MILLION/ Units)
        1. Drug Discovery
        2. Therapy Development
        3. Cancer
        4. Neurology
        5. Infectious Diseases
        6. Cardiovascular Diseases
        7. Others
      3. APAC Targeted Protein Degradation Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical & Biotechnology Companies
        2. Academic & Research Institutes
        3. Hospitals & Clinical Laboratories
        4. Others
      4. China
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      5. Korea
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      6. Japan
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      7. India
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      8. Australia
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      9. Taiwan
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      10. South East Asia
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      11. Rest of Asia-Pacific
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
    4. Middle East and Africa
      1. Middle East and Africa Targeted Protein Degradation Market By Type 2022-2034 (USD MILLION/ Units)
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
      2. Middle East and Africa Targeted Protein Degradation Market By Application 2022-2034 (USD MILLION/ Units)
        1. Drug Discovery
        2. Therapy Development
        3. Cancer
        4. Neurology
        5. Infectious Diseases
        6. Cardiovascular Diseases
        7. Others
      3. Middle East and Africa Targeted Protein Degradation Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical & Biotechnology Companies
        2. Academic & Research Institutes
        3. Hospitals & Clinical Laboratories
        4. Others
      4. UAE
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      5. Turkey
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      6. Saudi Arabia
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      7. South Africa
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      8. Egypt
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      9. Nigeria
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      10. Rest of MEA
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
    5. LATAM
      1. LATAM Targeted Protein Degradation Market By Type 2022-2034 (USD MILLION/ Units)
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
      2. LATAM Targeted Protein Degradation Market By Application 2022-2034 (USD MILLION/ Units)
        1. Drug Discovery
        2. Therapy Development
        3. Cancer
        4. Neurology
        5. Infectious Diseases
        6. Cardiovascular Diseases
        7. Others
      3. LATAM Targeted Protein Degradation Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Pharmaceutical & Biotechnology Companies
        2. Academic & Research Institutes
        3. Hospitals & Clinical Laboratories
        4. Others
      4. Brazil
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      5. Mexico
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      6. Argentina
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      7. Chile
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      8. Colombia
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
      9. Rest of LATAM
        1. PROTAC
        2. Molecular Glues
        3. LYTACs
        4. Others
        5. Drug Discovery
        6. Therapy Development
        7. Cancer
        8. Neurology
        9. Infectious Diseases
        10. Cardiovascular Diseases
        11. Others
        12. Pharmaceutical & Biotechnology Companies
        13. Academic & Research Institutes
        14. Hospitals & Clinical Laboratories
        15. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.